Edwards Lifesciences

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

CEO

Bernard J. Zovighian

CEOBernard J. Zovighian

Employees

16,000

Employees16,000

Headquarters

Irvine, California

HeadquartersIrvine, California

Founded

1958

Founded1958

Employees

16,000

Employees16,000

EW Key Statistics

Market cap

58.73B

Market cap58.73B

Price-Earnings ratio

59.48

Price-Earnings ratio59.48

Dividend yield

—

Dividend yield—

Average volume

6.03M

Average volume6.03M

High today

$102.19

High today$102.19

Low today

$98.50

Low today$98.50

Open price

$99.25

Open price$99.25

Volume

4.93M

Volume4.93M

52 Week high

$104.17

52 Week high$104.17

52 Week low

$74.66

52 Week low$74.66

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $102.10, with a market capitalization of 58.73B. The stock trades at a price-to-earnings (P/E) ratio of 59.48.

During the trading session on 2026-11-07, Edwards Lifesciences(EW) shares reached a daily high of $102.19 and a low of $98.50. At a current price of $102.10, the stock is +3.7% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 4.93M, compared to an average daily volume of 6.03M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $104.17 and a low of $74.66.

EW News

Simply Wall St 23h

Edwards Lifesciences Could Be 21% Undervalued After Earnings Guidance And Trial Data

Edwards Lifesciences (EW) is back in focus after a busy early November, with third quarter results, higher full year sales guidance and fresh clinical trial dat...

Simply Wall St 2d

Edwards Lifesciences Stock Looks Fully Priced On Cash Flow

has delivered a strong share gain in recent years, and a fresh swing in sentiment after new clinical data now puts the spotlight squarely on one question for in...

Simply Wall St 3d

Edwards Lifesciences Trial Results Put Earlier TAVR Use In Focus

Edwards Lifesciences (NYSE:EW) reported that its PROGRESS Trial found clinical benefits for TAVR in moderate aortic stenosis patients. The study showed reducti...

Analyst ratings

83%

of 29 ratings

Buy

82.8%

Hold

17.2%

Sell

More EW News

TipRanks 5d

Edwards Lifesciences: PROGRESS Trial Supports TAVR Expansion in Selected Moderate Aortic Stenosis Patients

Edwards Lifesciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed from Bank of America Securities main...

Simply Wall St 6d

Is FDA Valve Repair Approval Altering The Investment Case For Edwards Lifesciences?

Edwards Lifesciences recently secured FDA approval for its PASCAL Precision system for tricuspid valve repair and the PASCAL Ace with Capture Clarity system for...

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.